DreaMed Receives FDA Approval To Market Diabetes Management Platform

June 20, 2018 | DreaMed, the Israeli developer of diabetes management solutions, announced Monday that the U.S. Food and Drug Administration approved for marketing its Advisor Pro software decision-support platform for assisting healthcare professionals in the management and treatment of Type 1 diabetes. It uses proprietary algorithms combining event-drive, machine learning and fuzzy logic technologies to process data from a range of connected devices, including insulin pumps and self-management glucometers. The data is then analyzed to provide an optimized insulin dosing treatment plan to maintain balanced glucose levels. “Type 1 diabetes, managed with greater attention, leads to improved patient quality of life and reduced payer health-related costs,” DreaMed CEO Eran Atlas said in a statement. The software is currently targeting around 500,000 U.S. patients with Type 1 diabetes who use pumps and according to the company, the number is growing. Advisor Pro received regulatory approval in the European Union. To date, DreaMed has raised $6.5 million form investors like Jerusalem-based equity crowdfunding platform OurCrowd, Norma Investments which represents businessman Roman Abramovich and Medtronic. Based in Petah Tikva, the company was founded in 2014 by Eran Atlas and Shahar Miller.